In a patent infringement lawsuit brought under the Hatch-Waxman Act, the district court in the Northern District of West Virginia recently denied Plaintiffs Bausch Health Ireland Limited.
Jublia® (efinaconazole)
Case Name:
Valeant Pharm. N. Am. LLC v. Mylan Pharm. Inc.,978 F.3d 1374 (Fed. Cir. Nov. 5, 2020)(Circuit Judges Newman, O’Malley, and Taranto presiding; Opinion by O’Malley, J.) (Appeal from D.N.J., Sheridan, J.)
Drug Product and Patent(s)-in-Suit: Jublia® (efinaconazole); N/A
Nature of the Case and Issue(s) Presented: Plaintiffs owned the NDA covering Jublia, a drug that treated fungal infections (onychomycosis) of toenails. Defendant Mylan Pharmaceuticals Inc. (“MPI”) was a West Virginia corporation with a principal place of business in Morgantown, West Virginia. Defendant Mylan Inc. was a Pennsylvania corporation with a principal place of business in Canonsburg, Pennsylvania. Defendant Mylan Laboratories Ltd. (“MLL”) was an Indian corporation with a principal place of business in Hyderabad, India.